Description:
Explore the dynamic world of cell and gene therapy deal-making with Kalorama Information’s comprehensive report, Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023. This report tracks the deal-making activities in cell and gene therapy since 2021, providing insightful graphs of quarterly trends from 2021-2023 and detailing over 2,000 deals covering the Q1 2022-Q3 2023 period.
Key Features:
- In-depth analysis of over 2,000 deals in the cell and gene therapy sector
- Overview of quarterly funding amounts from 2021-2023
- Detailed breakdown of deal types, including Technology/Research/Strategic Collaboration, Venture Capital/Private Investment, Acquisition, Merger, Strategic Investment, and more
- Identification of the most active deal-making companies and their involvement in various types of deals
- Regional breakdown of deal-making activities in North America, Europe, APAC, and Rest of World
Market Insights:
The report highlights the significant growth and evolution of the cell and gene therapy sector, driven by advancements in enabling technologies such as CRISPR and next-generation sequencing. With over 1,500 therapy or tools companies now involved in this field, the market has become highly competitive, with over $20 billion in deals tracked in the first three quarters of 2023 alone.
Why Choose Kalorama Information’s Report:
Kalorama’s report provides a comprehensive overview of the current cell and gene therapy deal-making landscape, offering valuable insights for companies entering or already operating in this market. With detailed analysis of deal trends, funding amounts, and regional activities, this report is essential for understanding the dynamics that will shape the future of cell and gene therapy.
As the cell and gene therapy market continues to grow rapidly, understanding the deal-making landscape is crucial for identifying opportunities and staying competitive. Kalorama’s report offers unparalleled insights into the market, making it a valuable resource for companies looking to navigate the complex world of cell and gene therapy deal-making.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Total Quarterly Funding, by Type, Q1-Q3 2023 ($M)
| Type | Q1 | Q2 | Q3 | Partial ’23 | ’23 share |
| M&A | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| VC/private | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| IPO/FPO | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Collaboration payments | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| SPAC | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Strategic investments | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
